Holen Sie sich die Stockscreener-App
1.15
1.77%
0.02
Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten
Citius Oncology and Uniphar sign European distribution deal for Lymphir - Yahoo Finance
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
Citius inks EU distribution agreement for CTCL treatment - The Pharma Letter
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - PR Newswire
Biopharmaceutical company Citius Oncology announced that it has signed an exclusive distribution agreement with Europe's leading healthcare product provider Uniphar, officially expanding the commercialization of its innovative lymphoma therapy Lymphir - Bitget
Citius Oncology (CTOR) Projected to Post Quarterly Earnings on Friday - Defense World
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Up 22.3% in January - MarketBeat
CEO Moves: Why is Citius Oncology Inc stock going down2025 Trading Recap & Smart Investment Allocation Insights - baoquankhu1.vn
Aug Reactions: Can HCSG maintain sales growthJuly 2025 Setups & Growth Focused Investment Plans - baoquankhu1.vn
Decliners Report: Is Citius Oncology Inc undervalued by DCF analysisJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
Why Citius Oncology Inc. stock attracts global investorsEarnings Risk Report & Reliable Trade Execution Plans - bollywoodhelpline.com
Dow Update: Why is Citius Oncology Inc stock going downWeekly Profit Analysis & Long Hold Capital Preservation Plans - baoquankhu1.vn
Short Interest in Citius Oncology, Inc. (NASDAQ:CTOR) Expands By 51.2% - MarketBeat
Profit Review: Is Citius Oncology Inc likely to announce a buybackJuly 2025 PreEarnings & Weekly Stock Breakout Alerts - baoquankhu1.vn
Citius Oncology, Inc. (NASDAQ:CTOR): Is Breakeven Near? - simplywall.st
Can Citius Oncology Inc. stock beat market expectations this quarterJuly 2025 Setups & Long-Term Capital Growth Strategies - Улправда
Does Citius Oncology Inc. stock trade at a discount to peersPrice Action & Daily Chart Pattern Signals - Улправда
How buybacks impact Citius Oncology Inc. stock valueEarnings Growth Report & Expert Curated Trade Setups - Улправда
Aug Sectors: Why Citius Oncology Inc. stock attracts global investorsTrade Analysis Report & Weekly Watchlist of Top Performers - Улправда
Citius Oncology, Inc.Common Stock (NQ: CTOR - FinancialContent
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - GuruFocus
Citius Oncology raises $18M through direct offering - MSN
News | postregister.comCitius Oncology, Inc.Common Stock (Nasdaq:CTOR) Price Chart - FinancialContent
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR) - marketscreener.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR) - PR Newswire
Citius Oncology announces pricing of $9 million public offering - MSN
What drives Citius Oncology Inc stock priceVolatility Trading Techniques & You’ve Never Seen Stock Picks Like These - earlytimes.in
Is Citius Oncology Inc a good long term investmentBear Market Strategies & Low Entry Risk Stocks - earlytimes.in
Earnings Miss: Will Citius Oncology Inc stock sustain high P E ratiosJuly 2025 Institutional & Verified Technical Signals - Bộ Nội Vụ
Citius Oncology, Inc. (NASDAQ:CTOR) Sees Significant Increase in Short Interest - Defense World
Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - 富途牛牛
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update - MarketBeat
Citius Oncology (CTOR) Stock Analysis Report | Financials & Insights - Benzinga France
Citius Oncology’s Lymphir FDA win clouded by high upfront costs, regulatory risks, and uncertain market adoption - MSN
Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption - TipRanks
Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why - Benzinga
Citius Oncology, Inc. Full Year Loss Increases - Nasdaq
Citius Oncology Transitions to Commercial Stage: Analyzing the 10-K Filing and the 2026 Outlook for LYMPHIR - FinancialContent
Citius Oncology (NASDAQ:CTOR) Issues Quarterly Earnings Results - MarketBeat
Citius Oncology Fiscal 2025 Loss Widens - marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - WV News
Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView — Track All Markets
Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - marketscreener.com
Citius Oncology : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com
Citius Oncology Earnings Notes - Trefis
Citius Oncology, Inc.(NasdaqCM: CTOR) added to Russell 3000E Growth Index - MarketScreener
Citius Oncology (CTOR) Price Target Increased by 100.00% to 6.12 - MSN
Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria
Citius Oncology Raises $18M Through Direct Offering - TipRanks
Citius Oncology Announces Closing of $18 Million Concurrent Regi - GuruFocus
Citius Oncology closes $18 million in offerings to support LYMPHIR launch By Investing.com - Investing.com South Africa
0.56%
10.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):